All In Biotech

Drug Trial Radar · NCT05163886

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Dec 23, 2021

Primary completion

Jan 11, 2023

Study completion May 31, 2025

Sponsor

Lead sponsor
IRulya Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).

Conditions

  • Amyotrophic Lateral Sclerosis
  • ALS

Interventions

  • LAM-002ADrug

    LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.

  • PlaceboOther

    Microcrystalline cellulose in Swedish orange, size 0 capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of LAM-002A: Occurrence of TEAEs and SAEsTime frame: 24 Weeks
  2. Tolerability of LAM-002A: Completion of Core Study TreatmentTime frame: 12 Weeks
  3. Plasma Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks
  4. CSF Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.